Skip to content Skip to footer
Subscribe Now
NEWS

Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders

Shots: Gilead has entered into a strategic collaboration with LEO Pharma to develop the latter’s small molecule oral STAT6 programs targeting various inflammatory disorders As per the terms, Gilead secures worldwide rights to develop, manufacture & commercialize LEO’s preclinical STAT6 inhibitors & degrading proteins, with LEO having the option to co-commercialize them for dermatology…
January 13, 2025

Read more

NEWS

Telix to Acquire Therapeutic Assets & Biologics Platform from ImaginAb for ~$230M

Shots: Telix to acquire next-gen. therapeutic pipeline, biologics tech platform as well as research facility focused on protein engineering & discovery from ImaginAb via an asset purchase agreement to bolster its capabilities As per the terms, Telix will acquire candidates incl. DLL3 & integrin αvβ6 antagonist, plus a tech platform utilizing small engineered Ab…
January 13, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (January 06, 2025 – January 10, 2025)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & Biotech. Check out our full report below:     Oculis Reports Results from P-II (ACUITY) Study of OCS-05 for Treating Acute Optic Neuritis Read More: Oculis PharmaEssentia Reports Topline Data from P-III (SURPASS-ET) Trial of Ropeginterferon Alfa-2b-Njft (P1101) in Essential…
January 10, 2025

Read more

NEWS

Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio

Shots: Veralox has signed an exclusive agreement to acquire Nudge Therapeutics & its preclinical cyclic AMP-GMP (cGAS) inhibitors. The financial terms were undisclosed As per the terms, Veralox will resume the development of acquired candidates & initiate acquisition upon achievement of downstream milestones In addition, Veralox is developing VLX-1005 (12-LOX inhibitor) for thrombosis linked…
January 10, 2025

Read more

NEWS

Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

Shots: BI has entered into an agreement with Synaffix (Lonza’s company) to license the latter’s ADC technology, boosting its oncology pipeline via NBE Therapeutics (BI’s subsidiary) As per the terms, BI will access Synaffix’s platform for a specified but undisclosed number of targets, with the first target nominated & others to follow within a…
January 10, 2025

Read more

NEWS

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

Shots: Light Horse has entered into a multi-target partnership with Novartis to discover & develop FIC targets for cancer treatment by using its proprietary chemical libraries & precision genetic editing platform that identifies novel functional domains in disease-critical targets As per the agreement, Light Horse is entitled to receive $25M upfront, $1B research, development…
January 10, 2025

Read more

NEWS

Transcarent to Acquire Accolade for ~$621M

Shots: Transcarent to acquire Accolade with a total equity value of ~$621M, with shareholders receiving $7.03/share in cash, making Accolade private. Closing expected in Q2’25 The acquisition will yield a unified platform with Transcarent’s WayFinding (generative AI), pharmacy benefits & overall care experiences (incl. weight health, cancer & surgery care) & Accolade’s data of…
January 9, 2025

Read more

NEWS

Vividion Therapeutics to Bolster its Genomic Abilities Through the Acquisition of Tavros Therapeutics

Shots: Vividion (Bayer’s subsidiary) has acquired Tavros to strengthen its genomic capabilities via Tavros’ platform. The financial terms are undisclosed The acquisition strengthens Vividion’s functional genomics expertise by adding proprietary genomic screening approaches to discover new targets & translate the known ones. Combining resources from both the companies will enable drug discovery in oncology…
January 9, 2025

Read more

Load more